Amplified pancreatitis risk with GLP-1 mimetics, glucocorticoids
- PDF / 131,059 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 78 Downloads / 161 Views
1
Amplified pancreatitis risk with GLP-1 mimetics, glucocorticoids According to two studies published in JAMA Internal Medicine, current oral glucocorticoid use or use of glucagon-like peptide 1 (GLP-1)–based therapies are associated with an increased risk of acute pancreatitis.1,2 In the first study, a large administrative database in the US was analysed to investigate the association between GLP-1–based therapies, such as exenatide and sitagliptin, and the risk of acute pancreatitis among patients with type 2 diabetes mellitus. The study included 1269 patients admitted to hospital with acute pancreatitis and 1269 matched control patients.1 The findings show that patients taking GLP-1-based therapies had double the risk for hospital admission for acute pancreatitis compared with patients with type 2 diabetes not taking these drugs. After adjusting for available confounders, including metformin use, the risk of acute pancreatitis was significantly higher among current users of GLP-1–based therapies (adjusted odds ratio 2.24; 95% CI 1.36, 3.68) and with recent users (2.01; 1.37, 3.18) compared with nonusers. In the second study, researchers from Sweden conducted a nationwide population-based case-control study to investigate the potential association between oral glucocorticoid use and acute pancreatitis. Data from a Swedish registry were evaluated, where a total of 6161 cases with a first episode of acute pancreatitis and 61 637 controls were identified for the final analysis.2 They reported that the risk of acute pancreatitis was increased among current users of oral glucocorticoids compared with nonusers (odds ratio 1.53; 1.27, 1.84). Additionally, the risk was found to be the highest within 4 to 14 days after the initiation of glucocorticoids (1.73; 1.31, 2.28). Of note, there was no increased risk of acute pancreatitis among former or recent users of glucocorticoids compared with nonusers. 1. Singh S, et al. Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus - A Population-Based Matched Case-Control Study. JAMA Internal Medicine : [6 pages], 25 Feb 2013. Available from: URL: http://dx.doi.org/10.1001/ jamainternmed.2013.2720. 2. Sadr-Azodi O, et al. Association of Oral Glucocorticoid Use With an Increased Risk of Acute Pancreatitis - A Population-Based Nested Case-Control Study. JAMA Internal Medicine : [6 pages], 25 Feb 2013. Available from: URL: http:// dx.doi.org/10.1001/jamainternmed.2013.2737. 801161308
0114-9954/10/1442-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 9 Mar 2013 No. 1442
Data Loading...
